Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's leadership, including George Lasezkay, President and CEO, and Victor Chong, Chief Medical Officer and EVP of Research & Development, will engage in a fireside chat on Monday, April 7, 2025, at 12:45 p.m. ET. The presentation will be accessible via webcast through Clearside's website under the Investors section, with the recording remaining available for three months.
Clearside Biomedical (Nasdaq: CLSD), un'azienda biofarmaceutica focalizzata sulla somministrazione di terapie per la parte posteriore dell'occhio attraverso lo spazio suprachoroidale (SCS®), ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute.
Il leadership dell'azienda, inclusi George Lasezkay, Presidente e CEO, e Victor Chong, Direttore Medico e EVP di Ricerca e Sviluppo, parteciperanno a una chiacchierata informale lunedì, 7 aprile 2025, alle 12:45 ET. La presentazione sarà accessibile tramite webcast sul sito web di Clearside nella sezione Investitori, con la registrazione disponibile per tre mesi.
Clearside Biomedical (Nasdaq: CLSD), una empresa biofarmacéutica centrada en ofrecer terapias para la parte posterior del ojo a través del espacio suprachoroidal (SCS®), ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham.
El liderazgo de la empresa, incluyendo a George Lasezkay, Presidente y CEO, y Victor Chong, Director Médico y EVP de Investigación y Desarrollo, participará en una charla informal el lunes 7 de abril de 2025, a las 12:45 p.m. ET. La presentación estará disponible a través de un webcast en el sitio web de Clearside en la sección de Inversores, con la grabación accesible durante tres meses.
Clearside Biomedical (Nasdaq: CLSD), 눈의 뒤쪽에 치료제를 전달하는 데 초점을 맞춘 생물 제약 회사가 제24회 연례 니드햄 가상 의료 컨퍼런스에 참여한다고 발표했습니다.
회사의 리더십, 조지 라세즈카이 사장 겸 CEO와 빅터 총 최고 의학 책임자 및 연구개발 EVP가 2025년 4월 7일 월요일 오후 12시 45분 ET에 대화형 토크를 진행할 것입니다. 발표는 Clearside 웹사이트의 투자자 섹션을 통해 웹캐스트로 접근 가능하며, 녹화는 3개월 동안 이용할 수 있습니다.
Clearside Biomedical (Nasdaq: CLSD), une entreprise biopharmaceutique axée sur la délivrance de thérapies à l'arrière de l'œil par l'espace suprachoroïdal (SCS®), a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé.
La direction de l'entreprise, y compris George Lasezkay, Président et CEO, et Victor Chong, Directeur Médical et EVP de la Recherche et Développement, participera à une discussion informelle le lundi 7 avril 2025, à 12h45 ET. La présentation sera accessible par webcast via le site de Clearside dans la section Investisseurs, avec l'enregistrement disponible pendant trois mois.
Clearside Biomedical (Nasdaq: CLSD), ein biopharmazeutisches Unternehmen, das sich auf die Bereitstellung von Therapien für die Rückseite des Auges durch den suprachoroidalen Raum (SCS®) konzentriert, hat seine Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham bekannt gegeben.
Die Unternehmensführung, darunter George Lasezkay, Präsident und CEO, sowie Victor Chong, Chief Medical Officer und EVP für Forschung und Entwicklung, wird am Montag, den 7. April 2025, um 12:45 Uhr ET an einem informellen Gespräch teilnehmen. Die Präsentation wird über einen Webcast auf der Website von Clearside im Bereich Investoren zugänglich sein, und die Aufzeichnung bleibt drei Monate lang verfügbar.
- None.
- None.
ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 12:45 p.m. ET.
A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
When is Clearside Biomedical's (CLSD) presentation at the Needham Healthcare Conference?
How can investors access Clearside Biomedical's (CLSD) Needham Conference presentation?
How long will Clearside Biomedical's (CLSD) Needham Conference presentation be available for replay?
Which Clearside Biomedical (CLSD) executives are participating in the Needham Healthcare Conference?
What is Clearside Biomedical's (CLSD) main technological focus?
